ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,352Medicare Part D Prescriptions Filled, Including Refills

Rank: 171 out of 2094

$650K Total Retail Price of All Prescriptions

Rank: 297 out of 2094

546 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
85% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Jersey
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 546 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

2% of this provider’s 9,527 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

28% of this provider’s prescriptions were for brand-name drugs, compared to an average of 32%.

Prescription Price

$63 was the average price of a prescription from this provider, compared to $78 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Jersey
SIMVASTATIN 698 656 1 1
METFORMIN HCL 399 363 2 8
AMLODIPINE BESYLATE 378 367 3 2
LEVOTHYROXINE SODIUM 352 314 4 3
ALENDRONATE SODIUM 321 306 5 30
METOPROLOL TARTRATE 297 283 6 10
OMEPRAZOLE 295 286 7 4
AZITHROMYCIN 236 221 8 27
LISINOPRIL 233 220 9 7
ATENOLOL 226 213 10 21
ETODOLAC 202 195 11 344
DIOVAN 192 177 12 13
LOSARTAN POTASSIUM 185 171 13 17
SYMBICORT 175 175 14 149
FLUTICASONE PROPIONATE 173 154 15 41
GABAPENTIN 169 156 16 23
GLIPIZIDE 166 162 17 82
CLOPIDOGREL 158 137 18 22
DICLOFENAC SODIUM 156 147 19 168
MOMETASONE FUROATE 151 137 20 229
ATORVASTATIN CALCIUM 142 131 21 5
TAMSULOSIN HCL 131 119 22 29
GLYBURIDE-METFORMIN HCL 128 116 R 23 94
NEXIUM 128 107 23 16
FUROSEMIDE 125 125 25 6
HYDROCHLOROTHIAZIDE 108 108 26 12
LOVASTATIN 106 92 27 121
LEVOFLOXACIN 105 98 28 70
SINGULAIR 101 101 29 64
PLAVIX 90 83 30 38
MUPIROCIN 85 80 31 117
ADVAIR DISKUS 84 83 32 36
JANUVIA 81 77 33 35
VOLTAREN 76 76 34 109
CLOTRIMAZOLE-BETAMETHASONE 76 65 34 91
AMLODIPINE BESYLATE-BENAZEPRIL 70 70 36 58
MONTELUKAST SODIUM 69 66 37 128
TRIAMTERENE-HCTZ 68 68 38 87
RANITIDINE HCL 66 60 39 80
PROCTOZONE-HC 66 66 39 266
CELEBREX 64 64 41 74
PREDNISONE 61 59 42 54
TRAMADOL HCL 61 57 42 33
CLONIDINE HCL 58 47 44 62
WARFARIN SODIUM 53 53 45 11
FINASTERIDE 53 51 45 97
HALOBETASOL PROPIONATE 52 47 47 368
FEXOFENADINE HCL 52 37 47 191
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 10, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.